Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.48 |
| ▸ | BCHE | P06276 | 6/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL268686 | 0.81 | L3MBTL1 (0.46) | NPC1RAB9ALMNAHTTSMN1; SMN2 | |
| SCHEMBL923969 | 0.80 | CYP1A2 (0.46) | RAB9ALMNASMN1; SMN2 | |
| SCHEMBL11370324 | 0.79 | CA1 (0.50) | NPC1RAB9ALMNAHTTSMN1; SMN2 | |
| SCHEMBL1968557 | 0.78 | TDP1 (0.42) | ACHELMNASMN1; SMN2 | |
| SCHEMBL268626 | 0.78 | TDP1 (0.42) | ACHELMNASMN1; SMN2 | |
| SCHEMBL497246 | 0.78 | BRD4 (0.43) | — | |
| SCHEMBL496445 | 0.77 | RAB9A (0.46) | PTGS2NPC1RAB9ASMN1; SMN2ACACB | |
| SCHEMBL270922 | 0.77 | HDAC3 (0.42) | NPC1RAB9ALMNAHTT | |
| SCHEMBL496468 | 0.76 | KMT2A (0.50) | PTGS2LMNAHTT | |
| SCHEMBL14850018 | 0.73 | BCHE (0.53) | ACHEPTGS2BCHERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GLAXO GROUP LIMITED | 2008-12-18 | — | — | US | disclosed |
| EP-1902022-A1 | PIPERAZINE HETEROARYL DERIVATES AS GPR38 AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007007018-A1 | PIPERAZINE HETEROARYL DERIVATES AS GPR38 AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GPR68, GPR55, GPR88 | ACHE 3499/4885PTGS2 1390/4885BCHE 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.